NCT01092065View on ClinicalTrials.gov

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Parkinson's Disease
Interventions
DRUG

AFQ056 with L-dopa

hard gelatin capsule to be taken bid for six weeks

DRUG

Placebo

hard gelatin capsule to be taken bid for six weeks

Trial Locations (4)

46202

Indiana University School of Medicine, Indianapolis

66160

University of Kansas Medical Center - Parkinson's Disease and Movement Disorders Center, Kansas City

80113

Colorado Neurological Institute, Englewood

94085

The Parkinsons Institute, Sunnyvale

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY